Recital 15, Regulation (EU) 2024/2041

In forcesince 29 Jul 2024

Therefore, in view of the current prohibition of the use of monacolins from red yeast rice at levels of 3 mg and more per portion of the product recommended for daily consumption based on generally accepted scientific evidence and in view of legal certainty, the Commission must revoke the health claim on monacolin K from red yeast rice from the Union list of permitted health claims. Accordingly, the health claim on monacolin K from red yeast rice should no longer be used on foods.